Zetagen | Publications

The Future is About Personalised Medicine, Targeted Therapies, Immunotherapy, and Increasingly Precise Drug Delivery Working Together

September 22, 2026 | Opinion — Zetagen Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for primary and metastatic breast cancer, today announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet™ (Zeta BC 003) in subjects with metastatic breast cancer (MBC) with lytic bone lesions.

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Media Coverage

Media Coverage about Zetagen

The Future is About Personalised Medicine, Targeted Therapies, Immunotherapy, and Increasingly Precise Drug Delivery Working Together